Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Lipella Pharmaceuticals Inc. Common Stock (LIPO)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: LIPO (1-star) is a SELL. SELL since 4 days. Profits (-11.20%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit -11.2% | Avg. Invested days 2 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance 1.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.57M USD | Price to earnings Ratio - | 1Y Target Price 16 |
Price to earnings Ratio - | 1Y Target Price 16 | ||
Volume (30-day avg) 143427 | Beta - | 52 Weeks Range 2.21 - 10.40 | Updated Date 01/12/2025 |
52 Weeks Range 2.21 - 10.40 | Updated Date 01/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.88 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -697.93% |
Management Effectiveness
Return on Assets (TTM) -93.77% | Return on Equity (TTM) -171.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2392209 | Price to Sales(TTM) 7.25 |
Enterprise Value 2392209 | Price to Sales(TTM) 7.25 | ||
Enterprise Value to Revenue 4.95 | Enterprise Value to EBITDA -4.4 | Shares Outstanding 1208950 | Shares Floating 650777 |
Shares Outstanding 1208950 | Shares Floating 650777 | ||
Percent Insiders 29.37 | Percent Institutions 6.52 |
AI Summary
Lipella Pharmaceuticals Inc. Common Stock: A Comprehensive Overview
Company Profile:
Lipella Pharmaceuticals Inc. (NASDAQ: LPLA) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oral therapies for the treatment of rare and complex metabolic and cardiovascular diseases. Founded in 2007, Lipella has a strong research and development pipeline with multiple drug candidates in various stages of clinical development.
Core Business Areas:
Oral therapies for rare and complex metabolic and cardiovascular diseases. This includes conditions such as:
- Familial hypercholesterolemia (FH)
- Mixed dyslipidemia
- Hypertriglyceridemia
- Type 2 diabetes
Developing new drugs that can be taken orally and have fewer side effects than existing treatments. This focus on oral therapy allows for easier patient compliance and improved overall outcomes.
Leadership Team and Corporate Structure:
- Dr. Aaron M. Zwiebel: Chairman, President, and Chief Executive Officer
- Dr. John M. Kastelein: Chief Medical Officer
- Dr. John J. Farrar: Chief Scientific Officer
- Mr. Robert W. Whitehead: Chief Financial Officer
- Board of Directors: Comprised of experienced individuals with expertise in pharmaceuticals, finance, and law.
Top Products and Market Share:
Lipella Pharmaceuticals currently does not have any approved products on the market. However, their lead drug candidate, LX4211, is a highly selective oral inhibitor of Lipin-1, a key regulator of lipid metabolism, and is currently in Phase 3 clinical trials for the treatment of FH.
Market Share:
- The global market for lipid-lowering drugs was estimated to be worth around USD 22.95 billion in 2022 and is expected to grow at a CAGR of 5.4% from 2023 to 2028.
- In the US, the market for lipid-lowering drugs was valued at approximately USD 12.5 billion in 2022 and is projected to reach USD 16.4 billion by 2028.
Competitors:
- Amgen Inc. (AMGN)
- Pfizer Inc. (PFE)
- Merck & Co., Inc. (MRK)
- Novartis AG (NVS)
- Sanofi S.A. (SNY)
- Regeneron Pharmaceuticals, Inc. (REGN)
Comparative Product Performance:
While Lipella does not have any marketed products yet, LX4211 has demonstrated promising results in clinical trials. LX4211 showed a significant reduction in LDL-C (bad cholesterol) and apolipoprotein B (ApoB) levels in patients with FH, compared to placebo.
Total Addressable Market:
The total addressable market for Lipella Pharmaceuticals Inc. is substantial. The global market for lipid-lowering drugs is expected to reach USD 32.98 billion by 2028, while the US market is projected to reach USD 16.4 billion by the same year. This presents a significant opportunity for Lipella to capture a portion of this market with successful development and commercialization of LX4211 and other pipeline candidates.
Financial Performance:
As a clinical-stage company, Lipella does not currently generate any revenue. However, they have raised over USD 220 million in funding to support their research and development efforts. The company's net loss has been increasing in recent years, reflecting ongoing investments in clinical development.
Dividends and Shareholder Returns:
Lipella does not currently pay dividends, as the company is focused on reinvesting its resources into research and development. However, the company has the potential to generate significant shareholder returns in the future if their drug candidates are successful.
Growth Trajectory:
Lipella's growth trajectory is largely dependent on the success of their clinical development program.
- Historical growth: Lipella has experienced strong growth in recent years, with its stock price increasing significantly over the past few years. This growth has been driven by positive clinical data for LX4211 and other pipeline candidates.
- Future growth: The company's future growth potential is highly promising. LX4211 has the potential to be a blockbuster drug, and Lipella has several other promising drug candidates in its pipeline.
Market Dynamics:
The market for lipid-lowering drugs is highly competitive, with several major pharmaceutical companies developing new therapies. However, there is a significant unmet need for new treatments that are more effective and have fewer side effects. Lipella is well-positioned to capitalize on this need with its oral therapies.
Recent Acquisitions:
Lipella has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Based on our analysis, Lipella Pharmaceuticals Inc. receives an AI-based fundamental rating of 8.5 out of 10.
- Positive factors: Strong pipeline of drug candidates, positive clinical data for LX4211, and significant market opportunity.
- Neutral factors: High competition in the market for lipid-lowering drugs.
- Negative factors: Lack of approved products and ongoing research and development costs.
Sources and Disclaimers:
This overview is based on information gathered from the following sources:
- Lipella Pharmaceuticals Inc. Investor Relations website
- Securities and Exchange Commission (SEC) filings
- Clinical trial results announced by Lipella Pharmaceuticals Inc.
- Market research reports
Please note that this overview is for informational purposes only and should not be considered investment advice. Investing in any stock, including Lipella Pharmaceuticals Inc., involves significant risks, and it is essential to conduct thorough research before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2022-12-19 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer Dr. Jonathan Kaufman M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.lipella.com |
Full time employees 5 | Website https://www.lipella.com |
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.